NEW
Pagenax

Pagenax

Manufacturer:

Novartis

Distributor:

DKSH
Concise Prescribing Info
Contents
Brolucizumab
Indications/Uses
Neovascular (wet) age-related macular degeneration (AMD).
Dosage/Direction for Use
6 mg intravitreal inj every 4 wk for 1st 3 doses, then individualize treatment intervals based on disease activity. Patient w/o disease activity Treatment every 12 mth, patient w/ disease activity Treatment every 8 wk.
Contraindications
Hypersensitivity. Active or suspected ocular/periocular infections; active intraocular inflammation.
Special Precautions
Discontinue use in patients w/ rhegmatogenous retinal detachment, or stage 3 or 4 macular holes. Endophthalmitis, intraocular inflammation, traumatic cataract, retinal detachment; retinal vasculitis &/or vascular occlusion; risk factors for retinal pigment epithelial tears. History of stroke, transient ischaemic attacks or MI w/in last 3 mth. Immunogenicity. Bilateral treatment. Monitor & manage for increased IOP & optic nerve head perfusion. Not to be used concurrently w/ other systemic or local anti-VEGF medicinal products. Hepatic impairment. May affect ability to drive or use machines. Women of childbearing potential should use effective contraception. Not to be used during pregnancy. Not recommended in lactation. Childn & adolescents <18 yr.
Adverse Reactions
Hypersensitivity; reduced visual acuity; retinal haemorrhage & tear; uveitis, iritis; vitreous detachment & floaters; cataract, conjunctival haemorrhage, eye pain, increased IOP, conjunctivitis, retinal pigment epithelial tear, blurred vision, corneal abrasion, punctate keratitis.
ATC Classification
S01LA06 - brolucizumab ; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.
Presentation/Packing
Form
Pagenax intraocular inj 120 mg/mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in